Portaero, developer of a device used to treat chronic obstructive pulmonary diseases -- particularly emphysema -- has raised the bulk of its targeted $12 million round of equity, according to regulatory filings. It is still short $182,000. Based in Cupertino, Calif., the company, which lacks a web site, has taken capital from Aberdare Ventures, Novartis Venture Funds and Versant Ventures.